Principal Financial Group Inc Biomarin Pharmaceutical Inc Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

A detailed history of Principal Financial Group Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 458,039 shares of BMRN stock, worth $29 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
458,039
Previous 649,460 29.47%
Holding current value
$29 Million
Previous $53.5 Million 39.79%
% of portfolio
0.02%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024
SELL
$69.02 - $93.84 $13.2 Million - $18 Million
-191,421 Reduced 29.47%
458,039 $32.2 Million
Q2 2024

Jul 29, 2024
BUY
$74.43 - $92.22 $45.9 Million - $56.8 Million
616,301 Added 1858.62%
649,460 $53.5 Million
Q1 2024

Apr 29, 2024
BUY
$83.81 - $99.0 $289,395 - $341,847
3,453 Added 11.62%
33,159 $2.9 Million
Q4 2023

Feb 07, 2024
SELL
$76.22 - $98.51 $220,885 - $285,481
-2,898 Reduced 8.89%
29,706 $2.86 Million
Q3 2023

Nov 02, 2023
BUY
$85.07 - $94.48 $101,233 - $112,431
1,190 Added 3.79%
32,604 $2.88 Million
Q2 2023

Aug 07, 2023
SELL
$86.68 - $100.3 $287,430 - $332,594
-3,316 Reduced 9.55%
31,414 $2.72 Million
Q1 2023

May 09, 2023
BUY
$87.74 - $117.27 $78,702 - $105,191
897 Added 2.65%
34,730 $3.38 Million
Q4 2022

Feb 09, 2023
SELL
$80.93 - $108.63 $1.94 Million - $2.61 Million
-24,014 Reduced 41.51%
33,833 $3.5 Million
Q3 2022

Nov 09, 2022
BUY
$82.16 - $96.94 $1.1 Million - $1.3 Million
13,372 Added 30.07%
57,847 $4.9 Million
Q2 2022

Aug 10, 2022
BUY
$71.48 - $86.85 $85,275 - $103,612
1,193 Added 2.76%
44,475 $3.69 Million
Q1 2022

May 09, 2022
BUY
$74.28 - $92.69 $335,522 - $418,680
4,517 Added 11.65%
43,282 $3.34 Million
Q4 2021

Feb 09, 2022
SELL
$71.72 - $91.47 $1.18 Million - $1.51 Million
-16,502 Reduced 29.86%
38,765 $3.42 Million
Q3 2021

Nov 09, 2021
SELL
$74.77 - $85.47 $478,154 - $546,580
-6,395 Reduced 10.37%
55,267 $4.27 Million
Q2 2021

Aug 10, 2021
SELL
$75.51 - $84.79 $27,561 - $30,948
-365 Reduced 0.59%
61,662 $5.15 Million
Q1 2021

May 10, 2021
BUY
$74.73 - $90.69 $242,872 - $294,742
3,250 Added 5.53%
62,027 $4.68 Million
Q4 2020

Feb 08, 2021
BUY
$72.61 - $90.2 $918,371 - $1.14 Million
12,648 Added 27.42%
58,777 $5.15 Million
Q3 2020

Nov 06, 2020
SELL
$71.87 - $131.03 $313,353 - $571,290
-4,360 Reduced 8.64%
46,129 $3.51 Million
Q2 2020

Aug 05, 2020
BUY
$79.55 - $124.22 $613,250 - $957,611
7,709 Added 18.02%
50,489 $6.23 Million
Q1 2020

May 12, 2020
BUY
$71.37 - $96.85 $123,969 - $168,228
1,737 Added 4.23%
42,780 $3.62 Million
Q4 2019

Feb 05, 2020
BUY
$64.27 - $86.37 $127,383 - $171,185
1,982 Added 5.07%
41,043 $3.47 Million
Q3 2019

Nov 13, 2019
SELL
$67.4 - $85.11 $127,655 - $161,198
-1,894 Reduced 4.62%
39,061 $2.63 Million
Q2 2019

Aug 12, 2019
BUY
$80.35 - $93.9 $45,638 - $53,335
568 Added 1.41%
40,955 $3.51 Million
Q1 2019

May 10, 2019
BUY
$84.2 - $98.62 $242,496 - $284,025
2,880 Added 7.68%
40,387 $3.59 Million
Q4 2018

Feb 14, 2019
SELL
$80.14 - $106.07 $521,631 - $690,409
-6,509 Reduced 14.79%
37,507 $3.19 Million
Q3 2018

Nov 14, 2018
BUY
$93.92 - $105.72 $161,354 - $181,626
1,718 Added 4.06%
44,016 $4.27 Million
Q2 2018

Aug 13, 2018
BUY
$76.01 - $99.03 $194,433 - $253,318
2,558 Added 6.44%
42,298 $0
Q1 2018

May 14, 2018
BUY
$77.67 - $92.63 $82,796 - $98,743
1,066 Added 2.76%
39,740 $3.22 Million
Q4 2017

Feb 13, 2018
BUY
$80.76 - $95.13 $982,849 - $1.16 Million
12,170 Added 45.92%
38,674 $3.45 Million
Q3 2017

Nov 02, 2017
BUY
$80.6 - $94.95 $2.14 Million - $2.52 Million
26,504
26,504 $2.47 Million

Others Institutions Holding BMRN

# of Institutions
635
Shares Held
178M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email